Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2006

View Archived Issues

Merck & Co. licenses know how from Atugen

Phenoxodiol active in women with chemotherapy-resistant ovarian cancer

Lipocine completes product definition study on LPCN-1029

Millenia Hope advances programs in malaria and HIV/AIDS

Gen-Probe submits BLA amendment for Procleix Ultrio assay

Duke University to study bird flu vaccine dosing

BioSante profiles recent highlights

BioInvent and Immusol collaborate on antibody therapeutics for AMD

CF-101 to begin trial in dry eye symptoms, subject of MOU for Japan

Bioniche cleared for second phase III bladder cancer study of MCC

GSK and Sirna form RNAi strategic alliance in respiratory diseases

Pharmacopeia licenses DARA compounds from Bristol-Myers Squibb

Amgen completes acquisition of Abgenix

MediGene grants licenses to Virionics for CVLP vaccine program

Negative alpha-HGA results lead Tripep to refocus on ChronVac-C

Wyeth presents new orally active progesterone receptor antagonist

Aegera Therapeutics presents new BIR-binding XIAP antagonists for cancer

Histamine dihydrochloride, interleukin-2 beneficial in acute myeloid leukemia

Therapeutic agents for HIV infection disclosed in recent patent literature

New Astellas patent imparts novel treatment option for macular edema

CV Therapeutics and Actelion disclose novel agents for cardiovascular diseases

Sopherion designs potent mechanism-based antiangiogenic antitumor agents

Phase I study results for Conforma's ansamycin compound described at AACR meeting

Reata presents favorable preclinical data for RTA-502

Priority review granted to Neurodex NDA in emotional lability

Remicade sBLA for pediatric Crohn's disease granted priority review

SC-2-71: a thalidomide analogue with antiangiogenic and proapoptotic effects

Antiangiogenic AdNectin compound heading for clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...